Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Health Ministry’s Diovan Study Committee to Start on Aug 9, Minister Expects Attendance of Ex-Novartis Employee
August 5, 2013
- EAD Director to Personally Visit Hospitals to Urge Early Price Agreement
August 5, 2013
- Distribution Reform and Perpetuation of Premium for New Drug Development Are Immediate Top-Priority Issues: EAD Director Jo
August 2, 2013
- CSIMC Subcommittee Discusses Revisions of Drug Pricing Rules; Some Reps Oppose Proposed Rewards for Innovation
August 1, 2013
- “No Surprises” in TPP Negotiations; Gov’t Undecided Whether to Hold Briefing for the Drug Industry: PR Counselor Nakagawa
July 31, 2013
- Combination of Insured and Uninsured Treatments to Be a Top Priority Topic in Discussions by Council for Regulatory Reform
July 30, 2013
- PAFSC’s Second Committee Recommends Approval for Bronchial Asthma Treatment Flutiform, Others
July 29, 2013
- Half of All Drugs, Add’l Indications Approved from FY2009 to FY2012 Underwent Clinical Trials at NHO Hospitals
July 29, 2013
- MHLW-MEXT Joint Committee Agrees to Require Researchers to Store Clinical Research Data for Long Periods
July 26, 2013
- MHLW Might Submit Bill on Online OTC Sales to Extraordinary Diet Session: PFSB Head
July 25, 2013
- CSIMC Approves Questionnaire to Determine Impact of FY2012 Medical Fee Revision on Generic Drug Use
July 25, 2013
- Diovan Study Committee to Hold 1st Meeting in Early August: Minister
July 24, 2013
- Stivarga Effectively 1st Drug Offered under Japan’s “Compassionate Use” System
July 23, 2013
- Pilot Program for Japan-Version “Compassionate Use” System to Begin at National Cancer Center
July 23, 2013
- 1st Committee to Discuss Approval of New Products Including Janssen’s Extended Release Schizophrenia Treatment
July 23, 2013
- MHLW OKs AMD Clinical Research Using iPS Cells
July 22, 2013
- MHLW Mulls “Ultra-Orphan” Drug System; Designation Might Become Possible with Pre-Clinical, Healthy Subject Data
July 22, 2013
- US Aims for Lifting of Ban on Mixed Care: Prof. Murakami of Yamagata University
July 22, 2013
- South Korean MOHW Officials Announce Roadmap for South Korea to Become No. 7 Worldwide in New Drug Development by 2020
July 19, 2013
- CSIMC Begins Full-Scale Discussions on FY2014 NHI Price Revision; Generics as Well as Long-Listed Original Drugs May Face Further Price Cuts
July 19, 2013
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…